Volume : 13, Issue : 10, October – 2026

Title:

ARTIFICIAL INTELLIGENCE IN PHARMACY: APPLICATIONS, OPPORTUNITIES AND CHALLENGES

Authors :

Pragati Vikas Kokare*, Yukta Moreshwar Mahamuni, Pruthviraj Bhimrao Kokate, Dr. Ashish Jadhav

Abstract :

Artificial intelligence (AI) is reshaping every stage of the medicine life cycle, from the identification of drug targets to the counselling of patients at the pharmacy counter. This review examines how AI technologies, chiefly machine learning, deep learning, natural language processing and generative models, are applied across pharmaceutical science and pharmacy practice, and weighs the opportunities they offer against the challenges that limit their safe adoption. In drug discovery, AI supports target identification, protein structure prediction, virtual screening, de novo molecular design, retrosynthesis, drug repurposing and clinical trial optimisation. In pharmaceutics and manufacturing, it is used to predict formulation behaviour, guide three-dimensional printing of dosage forms and enable real-time process control. In clinical, hospital and community pharmacy, AI-enabled tools assist prescription verification, prevention of adverse drug events, dose individualisation, adherence support, inventory management and patient communication. AI also strengthens pharmacovigilance, regulatory science and pharmacy education. The principal opportunities are shorter development timelines, lower attrition, personalised therapy, safer medication use and more efficient operations. The principal challenges are poor data quality and bias, limited transparency of complex models, privacy, unclear accountability, evolving regulation, validation gaps, fabricated output from language models and the need to prepare the pharmacy workforce. We conclude that AI is best viewed as a decision-support partner that extends, and does not replace, the professional judgement of pharmacists and pharmaceutical scientists, and we outline priorities for responsible implementation.
Keywords: Artificial intelligence; Machine learning; Deep learning; Drug discovery; Pharmacy practice; Pharmacovigilance; Personalised medicine; Pharmaceutical manufacturing.

Cite This Article:

Please cite this article in press Pragati Vikas Kokare et al., Artificial Intelligence In Pharmacy: Applications, Opportunities And Challenges.,. Indo Am. J. P. Sci, 2026; 13(10)..

REFERENCES:

1. Russell S, Norvig P. Artificial intelligence: a modern approach. 4th ed. Hoboken (NJ): Pearson; 2020.
2. Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, et al. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017;2(4):230-43.
3. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
4. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng. 2018;2(10):719-31.
5. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20-33.
6. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844-53.
7. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40-51.
8. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12(7):3049-62.
9. Nelson SD, Walsh CG, Olsen CA, McLaughlin AJ, LeGrand JR, Schutz N, et al. Demystifying artificial intelligence in pharmacy. Am J Health Syst Pharm. 2020;77(19):1556-70.
10. Chalasani SH, Syed J, Ramesh M, Patil V, Pramod Kumar TM. Artificial intelligence in the field of pharmacy practice: a literature review. Explor Res Clin Soc Pharm. 2023;12:100346.
11. Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educ. 2023;23:689.
12. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80-93.
13. Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine learning and artificial intelligence in pharmaceutical research and development: a review. AAPS J. 2022;24(1):19.
14. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436-44.
15. Vaswani A, Shazeer N, Parmar N, Uszkoreit J, Jones L, Gomez AN, et al. Attention is all you need. In: Guyon I, Luxburg UV, Bengio S, Wallach H, Fergus R, Vishwanathan S, et al., editors. Advances in neural information processing systems 30. Red Hook (NY): Curran Associates; 2017. p. 5998-6008.
16. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-9.
17. Singhal K, Azizi S, Tu T, Mahdavi SS, Wei J, Chung HW, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172-80.
18. Thirunavukarasu AJ, Ting DSJ, Elangovan K, Gutierrez L, Tan TF, Ting DSW. Large language models in medicine. Nat Med. 2023;29(8):1930-40.
19. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347-58.
20. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-77.
21. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23(6):1241-50.
22. Kreimeyer K, Foster M, Pandey A, Arya N, Halford G, Jones SF, et al. Natural language processing systems for capturing and standardizing unstructured clinical information: a systematic review. J Biomed Inform. 2017;73:14-29.
23. Gómez-Bombarelli R, Wei JN, Duvenaud D, Hernández-Lobato JM, Sánchez-Lengeling B, Sheberla D, et al. Automatic chemical design using a data-driven continuous representation of molecules. ACS Cent Sci. 2018;4(2):268-76.
24. Walters WP, Murcko M. Assessing the impact of generative AI on medicinal chemistry. Nat Biotechnol. 2020;38(2):143-5.
25. Castelvecchi D. Can we open the black box of AI? Nature. 2016;538(7623):20-3.
26. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018;17(2):97-113.
27. Reker D, Schneider G. Active-learning strategies in computer-assisted drug discovery. Drug Discov Today. 2015;20(4):458-67.
28. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773-80.
29. Zhu H. Big data and artificial intelligence modeling for drug discovery. Annu Rev Pharmacol Toxicol. 2020;60:573-89.
30. Ching T, Himmelstein DS, Beaulieu-Jones BK, Kalinin AA, Do BT, Way GP, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141):20170387.
31. Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of artificial intelligence for computer-assisted drug discovery. Chem Rev. 2019;119(18):10520-94.
32. Schneider P, Walters WP, Plowright AT, Sieroka N, Listgarten J, Goodnow RA Jr, et al. Rethinking drug design in the artificial intelligence era. Nat Rev Drug Discov. 2020;19(5):353-64.
33. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688-702.e13.
34. Wong F, Zheng EJ, Valeri JA, Donghia NM, Anahtar MN, Omori S, et al. Discovery of a structural class of antibiotics with explainable deep learning. Nature. 2024;626(7997):177-85.
35. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37(9):1038-40.
36. Segler MHS, Preuss M, Waller MP. Planning chemical syntheses with deep neural networks and symbolic AI. Nature. 2018;555(7698):604-10.
37. Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, et al. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater. 2019;18(5):435-41.
38. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41-58.
39. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30-1.
40. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci. 2019;40(8):577-91.
41. Weissler EH, Naumann T, Andersson T, Ranganath R, Elemento O, Luo Y, et al. The role of machine learning in clinical research: transforming the future of evidence generation. Trials. 2021;22(1):537.
42. Lamberti MJ, Wilkinson M, Donzanti BA, Wohlhieter GE, Parikh S, Wilkins RG, et al. A study on the application and use of artificial intelligence to support drug development. Clin Ther. 2019;41(8):1414-26.
43. Jayatunga MKP, Xie W, Ruder L, Schulze U, Meier C. AI in small-molecule drug discovery: a coming wave? Nat Rev Drug Discov. 2022;21(3):175-6.
44. Jayatunga MKP, Ayers M, Bruens L, Jayanth D, Meier C. How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons. Drug Discov Today. 2024;29(6):104009.
45. Yang Y, Ye Z, Su Y, Zhao Q, Li X, Ouyang D. Deep learning for in vitro prediction of pharmaceutical formulations. Acta Pharm Sin B. 2019;9(1):177-85.
46. Bannigan P, Aldeghi M, Bao Z, Häse F, Aspuru-Guzik A, Allen C. Machine learning directed drug formulation development. Adv Drug Deliv Rev. 2021;175:113806.
47. Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. Adv Drug Deliv Rev. 2019;151-152:169-90.
48. Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023;15(7):1916.
49. Elbadawi M, Castro BM, Gavins FKH, Ong JJ, Gaisford S, Pérez G, et al. M3DISEEN: a novel machine learning approach for predicting the 3D printability of medicines. Int J Pharm. 2020;590:119837.
50. Rantanen J, Khinast J. The future of pharmaceutical manufacturing sciences. J Pharm Sci. 2015;104(11):3612-38.
51. Lee SL, O’Connor TF, Yang X, Cruz CN, Chatterjee S, Madurawe RD, et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Innov. 2015;10(3):191-9.
52. US Food and Drug Administration. Guidance for industry: PAT, a framework for innovative pharmaceutical development, manufacturing, and quality assurance. Rockville (MD): FDA; 2004.
53. International Council for Harmonisation. ICH harmonised tripartite guideline Q8(R2): pharmaceutical development. Geneva: ICH; 2009.
54. Bates DW, Levine D, Syrowatka A, Kuznetsova M, Craig KJT, Rui A, et al. The potential of artificial intelligence to improve patient safety: a scoping review. NPJ Digit Med. 2021;4(1):54.
55. Syrowatka A, Song W, Amato MG, Foer D, Edrees H, Co Z, et al. Key use cases for artificial intelligence to reduce the frequency of adverse drug events: a scoping review. Lancet Digit Health. 2022;4(2):e137-48.
56. Choudhury A, Asan O. Role of artificial intelligence in patient safety outcomes: systematic literature review. JMIR Med Inform. 2020;8(7):e18599.
57. Flynn EA, Barker KN, Carnahan BJ. National observational study of prescription dispensing accuracy and safety in 50 pharmacies. J Am Pharm Assoc (Wash). 2003;43(2):191-200.
58. Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database (Oxford). 2020;2020:baaa010.
59. Aldeer M, Javanmard M, Martin RP. A review of medication adherence monitoring technologies. Appl Syst Innov. 2018;1(2):14.
60. Labovitz DL, Shafner L, Reyes Gil M, Virmani D, Hanina A. Using artificial intelligence to reduce the risk of nonadherence in patients on anticoagulation therapy. Stroke. 2017;48(5):1416-9.
61. Sallam M. ChatGPT utility in healthcare education, research, and practice: systematic review on the promising perspectives and valid concerns. Healthcare (Basel). 2023;11(6):887.
62. Ji Z, Lee N, Frieske R, Yu T, Su D, Xu Y, et al. Survey of hallucination in natural language generation. ACM Comput Surv. 2023;55(12):248.
63. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427-36.
64. Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel PM. Innovation in pharmacovigilance: use of artificial intelligence in adverse event case processing. Clin Pharmacol Ther. 2019;105(4):954-61.
65. Ball R, Dal Pan G. “Artificial intelligence” for pharmacovigilance: ready for prime time? Drug Saf. 2022;45(5):429-38.
66. US Food and Drug Administration. Using artificial intelligence and machine learning in the development of drug and biological products: discussion paper and request for feedback. Silver Spring (MD): FDA; 2023.
67. US Food and Drug Administration. Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products: draft guidance for industry and other interested parties. Silver Spring (MD): FDA; 2025 Jan. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological
68. European Medicines Agency. Reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle. Amsterdam: EMA; 2024 Sep 30. Available from: https://www.ema.europa.eu/en/use-artificial-intelligence-ai-medicinal-product-lifecycle
69. European Medicines Agency, US Food and Drug Administration. Guiding principles of good AI practice in drug development. Amsterdam, Silver Spring (MD): EMA, FDA; 2026 Jan 14.
70. European Parliament, Council of the European Union. Regulation (EU) 2024/1689 of 13 June 2024 laying down harmonised rules on artificial intelligence (Artificial Intelligence Act). Off J Eur Union. 2024 Jul 12;L series:2024/1689.
71. World Health Organization. Ethics and governance of artificial intelligence for health: WHO guidance. Geneva: WHO; 2021.
72. Rasve V, Chakraborty AK, Jain SK, Vengurlekar S. Comparative evaluation of antidiabetic activity of ethanolic leaves extract of Clematis triloba and their SMEDDS formulation in streptozotocin-induced diabetic rats. J Popul Ther Clin Pharmacol. 2022;29(4):959-971. doi:10.53555/jptcp.v29i04.2360.
73. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nat Med. 2022;28(1):31-8.
74. Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319(13):1317-8.
75. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447-53.
76. Price WN 2nd, Cohen IG. Privacy in the age of medical big data. Nat Med. 2019;25(1):37-43.
77. Hasan HE, Jaber D, Khabour OF, Alzoubi KH. Ethical considerations and concerns in the implementation of AI in pharmacy practice: a cross-sectional study. BMC Med Ethics. 2024;25:55.
78. Government of India. The Digital Personal Data Protection Act, 2023 (Act No. 22 of 2023). New Delhi: Ministry of Law and Justice; 2023.
79. Vayena E, Blasimme A, Cohen IG. Machine learning in medicine: addressing ethical challenges. PLoS Med. 2018;15(11):e1002689.
80. Char DS, Shah NH, Magnus D. Implementing machine learning in health care: addressing ethical challenges. N Engl J Med. 2018;378(11):981-3.
81. Indian Council of Medical Research. Ethical guidelines for application of artificial intelligence in biomedical research and healthcare. New Delhi: ICMR; 2023.
82. Moor M, Banerjee O, Abad ZSH, Krumholz HM, Leskovec J, Topol EJ, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259-65.
83. Rieke N, Hancox J, Li W, Milletarì F, Roth HR, Albarqouni S, et al. The future of digital health with federated learning. NPJ Digit Med. 2020;3:119.